Type 2 diabetes drug alogliptin may have fallen short of regulatory approval in the United States, but its latest progress overseas is paying off for Furiex Pharmaceuticals (NASDAQ:FURX) in the form of a $10 million milestone payment. The marketing authorization application filed by drug partner Takeda Pharmaceutical (TYO:4502) was accepted and triggered the payment to […]
Diabetes drug alogliptin fell short of U.S. Food and Drug Administration approval on Wednesday, dealing a blow to the hopes of Takeda Pharmaceutical (TYO:4502) and its partner, Furiex Pharmaceuticals (NASDAQ:FURX). The complete response letter means Takeda will need to come up with more data if it wants to try again for FDA approval on its […]
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Takeda Pharmaceutical’s (TYO:4502) diabetes drug alogliptin failed to secure U.S. Food and Drug Administration approval. The agency issued a complete response letter for new drug applications of alogliptin and a combination drug that pairs alogliptin with another Takeda drug, Actos. “We will immediately request a meeting with the FDA to determine the appropriate next steps […]
Today we might glimpse the U.S. Food and Drug Administration’s thoughts on approving new type 2 diabetes drugs in a post-Avandia world. Nesina, a Takeda Pharmaceutical (TYO:4502) compound licensed from Furiex Pharmaceuticals (NASDAQ:FURX), is set for a prescription drug user fee act (PDUFA) decision today. The drug candidate, also known as alogliptin, was developed to […]
Furiex Pharmaceuticals (NASDAQ:FURX) must wait until April to learn whether the type 2 diabetes compound it licensed to a drug partner will secure regulatory approval and a $25 million milestone payment for the company. The U.S. Food and Drug Administration has notified drug partner Takeda Pharmaceuticals that review of investigational diabetes drug alogliptin has been […]
Furiex Pharmaceuticals (NASDAQ:FURX) has secured $15 million to finance R&D for three compounds in its drug pipeline. The Morrisville, North Carolina drug development company has entered into a loan agreement with MidCap Financial and Silicon Valley Bank (NASDAQ:SIVB). Furiex has already received the first tranche, $10 million. The second tranche of $5 million will only […]
Share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health, healthcare navigation, and more.
A type 2 diabetes drug hopefully thought of as a potential blockbuster before stalling amid safety concerns is now taking another shot at approval. Takeda Pharmaceuticals (TYO:4502), which is partnered with Morrisville, North Carolina-based Furiex Pharmaceuticals (NASDAQ:FURX) on the diabetes drug candidate alogliptin, has filed two new drug applications for the compound with the U.S. […]
Drug development company Furiex Pharmaceuticals (NASDAQ:FURX) has licensed an antibiotic compound that could be developed into a new weapon against antibiotic-resistant strains such as Methicillin-Resistant Staphylococcus aureus, or MRSA. Morrisville, North Carolina-based Furiex said it has acquired exclusive licensing rights to develop and commercialize JNJ-Q2 through its existing development and license agreement with Janssen Pharmaceutica. […]
Furiex Pharmaceuticals is on a faster path for regulatory review of its treatment for irritable bowel syndrome. The Morrisville, North Carolina-based company has received fast track designation on its drug candidate, a status reserved for drugs that address serious diseases and fill an unmet medical need.